Cited by 457Sarcoma Diagnosis and TreatmentCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.

Genome-Informed Targeted Therapy for Osteosarcoma

Open access

Sayles, Leanne C., Breese, Marcus R., Koehne, Amanda L., Leung, Stanley G., Lee, Alex G., Liu, Heng-Yi, Spillinger, Aviv, Shah, Avanthi T., Tanasa, Bogdan, Straessler, Krystal, Hazard, Florette K., Spunt, Sheri L., Marina, Neyssa, Kim, Grace E., Cho, Soo-Jin, Avedian, Raffi S., Mohler, David G., Kim, Mi-Ok, DuBois, Steven G., Hawkins, Douglas S., Sweet-Cordero, E. Alejandro·2019·Cancer Discovery

DOI 10.1158/2159-8290.cd-17-1152PMC PMC7134333

Open this paper in CoChat — free account

Abstract

Osteosarcoma is a highly aggressive cancer for which treatment has remained essentially unchanged for more than 30 years. Osteosarcoma is characterized by widespread and recurrent somatic copy-number alterations (SCNA) and structural rearrangements. In contrast, few recurrent point mutations in protein-coding genes have been identified, suggesting that genes within SCNAs are key oncogenic drivers in this disease. SCNAs and structural rearrangements are highly heterogeneous across osteosarcoma cases, suggesting the need for a genome-informed approach to targeted therapy. To identify patient-specific candidate drivers, we used a simple heuristic based on degree and rank order of copy-number amplification (identified by whole-genome sequencing) and changes in gene expression as identified by RNA sequencing. Using patient-derived tumor xenografts, we demonstrate that targeting of patient-specific SCNAs leads to significant decrease in tumor burden, providing a road map for genome-informed treatment of osteosarcoma. Significance: Osteosarcoma is treated with a chemotherapy regimen established 30 years ago. Although osteosarcoma is genomically complex, we hypothesized that tumor-specific dependencies could be identified within SCNAs. Using patient-derived tumor xenografts, we found a high degree of response for “genome-matched” therapies, demonstrating the utility of a targeted genome-informed approach. This article is highlighted in the In This Issue feature, p. 1

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-1152

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEMPreprint
Li, H. (2013) · arXiv (Cornell University) · doi:10.48550/arxiv.1303.3997 · Cited by 10,154
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Landscape of transcription in human cells
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012) · Nature · doi:10.1038/nature11233 · Cited by 5,187
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEMPreprint
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 5,155
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,926
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
DELLY: structural variant discovery by integrated paired-end and split-read analysis
Rausch, T., Zichner, T., Schlattl, A., Stütz, A. M., Beneš, V., & Korbel, J. O. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts378 · Cited by 2,438

Show all 78 references

Sorted by citations

Items 201–300 of 457

Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma
Torres, H. M., VanCleave, A. M., Vollmer, M. L., Callahan, D., Smithback, A., Conn, J. M., Rodezno, T. G., Gao, Z., Cao, Y. X., Tecleab, Y. A., et al. (2021) · Cancers · doi:10.3390/cancers13164199 · Cited by 10
The perplexing role of immuno-oncology drugs in osteosarcoma
Smrke, A., Tam, Y. B., Anderson, P. M., Jones, R. L., & Huang, P. H. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100400 · Cited by 9
Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden
Zheng, S., Wang, F., Huang, J., Zhou, Y., Yang, Q., Qian, G., Zhou, C., Min, D., Song, L., & Shen, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.625226 · Cited by 9
Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapy
Welch, D. L., Fridley, B. L., Cen, L., Teer, J. K., Yoder, S., Pettersson, F. H., Xu, L., Cheng, C., Zhang, Y., Alexandrow, M. G., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47412-1 · Cited by 8
Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma
Ma, Y., Cong, L., Shen, W., Yang, C., & Ye, K. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4080 · Cited by 10
Advances in osteosarcoma research: Pathogenesis and emerging therapeutic strategies
Yan, L. ‐., Dong, X., & Chen, S. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105252 · Cited by 10
Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-β Autocrine Stimulation
Solomon, P. E., Kirkemo, L. L., Wilson, G. M., Leung, K., Almond, M. H., Sayles, L. C., Sweet-Cordero, A., Rosenberg, O. S., Coon, J. J., & Wells, J. A. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100247 · Cited by 9
Self-citation
Immune-based prognostic biomarkers associated with metastasis of osteosarcoma
Ma, T., Peng, C., Wu, D., Yang, S., Li, J., Zhang, C., & Gao, C. (2023) · General Physiology and Biophysics · doi:10.4149/gpb_2022050 · Cited by 8
Genomic and transcriptomic characterization of pre-operative chemotherapy response in patients with osteosarcoma
Yang, Y., Huang, Z., Yuan, M., Rui, J., Chen, R., Jin, T., Sun, Y., Deng, Z., Shan, H., Niu, X., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46857-8 · Cited by 8
p38γ overexpression promotes osteosarcoma cell progression
Shi, C., Cheng, W., Wang, Y., Li, D., Zhou, L., Zhu, Y.-C., & Zhou, X. (2020) · Aging · doi:10.18632/aging.103708 · Cited by 8
The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis
Zhang, W., Ren, X., Qi, L., Zhang, C., Tu, C., & Li, Z. (2021) · BMC Cancer · doi:10.1186/s12885-021-07882-w · Cited by 8
Inhibition of sphingolipid metabolism in osteosarcoma protects against CD151-mediated tumorigenicity
Wang, H., Jin, X., Zhang, Y., Wang, Z., Zhang, T., Xu, J., Shen, J., Zan, P., Sun, M., Wang, C., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00900-9 · Cited by 8
Osteosarcoma tumors maintain intra-tumoral transcriptional heterogeneity during bone and lung colonizationPreprint
Rajan, S., Franz, E., McAloney, C. A., Vetter, T. A., Cam, M., Gross, A. C., Taslim, C., Wang, M., Cannon, M. V., Oles, A. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.03.367342 · Cited by 8
Structurally complex osteosarcoma genomes exhibit limited heterogeneity within individual tumors and across evolutionary time
Rajan, S., Zaccaria, S., Cannon, M. V., Cam, M., Gross, A. C., Raphael, B. J., & Roberts, R. D. (2021) · doi:10.1101/2021.08.30.458268 · Cited by 33
ACSL4 accelerates osteosarcoma progression via modulating TGF-β/Smad2 signaling pathway
Li, X., Chen, Q., Zhao, D., Tan, J., Liao, R., Gu, Y., Zhu, J., Zhang, H., Xie, J., & Chen, L. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04975-5 · Cited by 7
Single-Cell Spatial–Temporal Analysis ofZNF451in Mediating Drug Resistance and CD8+T Cell Dysfunction
Tang, N., Deng, W., Wu, Y., Deng, Z., Wu, X., Xiong, J., & Zhao, Q. (2024) · Research · doi:10.34133/research.0530 · Cited by 7
SNRNP70 regulates the splicing of CD55 to promote osteosarcoma progression
Li, W., Wang, L., Tian, W., Ji, W., Bing, D., Wang, Y., Xu, B., Feng, J., Zhang, P., Liang, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.185269 · Cited by 7
Inhibition of PERK pathway promotes TAMs M1 polarization and ER stress in Osteosarcoma cells hindering tumor progression
Li, X., Guo, X., Wang, W., & Liu, P. P. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115293 · Cited by 7
Impact of scaffold material choice on osteosarcoma phenotype and drug responses in 3D
Monette, C. E., Lee, J., Peasah, A. D., Sayles, L. C., Tai, M., Sweet-Cordero, A., & Yang, F. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.08.046 · Cited by 7
Self-citation
Exploring the Tumor Microenvironment in Osteosarcoma: Driver of Resistance and Progression
Schmidt, A. A., Prasad, A., Huisman, A. R., Wakefield, M. R., & Fang, Y. (2025) · Cancers · doi:10.3390/cancers17193106 · Cited by 9
Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment
Dong, Y., Wang, L., Zhang, H., Li, M., Luo, Z. Y., Hu, Y., & Cai, C.-Y. (2025) · Advanced Science · doi:10.1002/advs.202512363 · Cited by 8
Osteosarcoma Arising in Fibrous Dysplasia of the Long Bone: Characteristic Images and Molecular Profiles
Kim, H. G., Baek, J. H., & Na, K. (2022) · Diagnostics · doi:10.3390/diagnostics12071622 · Cited by 7
Spatiotemporal evolutionary process of osteosarcoma immune microenvironment remodeling and C1QBP‐driven drug resistance deciphered through single‐cell multi‐dimensional analysis
Wu, X., Tang, N., Zhao, Q., & Xiong, J. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10654 · Cited by 7
Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway
VanCleave, A. M., Palmer, M., Fang, F., de Oliveira, H. T., Rodezno, T. G., Li, Q., Fuglsby, K., Evans, C. M., Tecleab, Y. A., Ross, A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27611 · Cited by 7
Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma
Reinecke, J. B., & Roberts, R. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_7 · Cited by 7
MiR-129-5p Suppresses Cell Proliferation of Human Osteosarcoma Cancer by Down-Regulating LncRNA Lnc712
Yu, Y., Zuo, W., Cai, W., Xu, Y., Liu, W., & Zhao, Z. (2021) · Cancer Management and Research · doi:10.2147/cmar.s284078 · Cited by 7
GABPB1-AS1 Promotes the Development of Osteosarcoma by Targeting SP1 and Activating the Wnt/β-Catenin Pathway
Chen, J., Bian, M., Pan, L., Liu, C., & Yang, H. (2022) · Journal of Oncology · doi:10.1155/2022/8468896 · Cited by 7
A Multicentre Clinical Study of Sarcoma Personalised Treatment Using Patient-Derived Tumour Xenografts
Xu, H., Zheng, H. W., Zhang, Q., Song, H., Wang, Q., Xiao, J., Dong, Y., Shen, Z., Wang, S., Wu, S., et al. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.06.002 · Cited by 7
Long Noncoding RNA LINC00909 Induces Epithelial-Mesenchymal Transition and Contributes to Osteosarcoma Tumorigenesis and Metastasis
Liu, W., Zhang, Q., Shen, K., Li, K., Chang, J., Li, H., Duan, A., Zhang, S., & Huang, Y. (2022) · Journal of Oncology · doi:10.1155/2022/8660965 · Cited by 7
Dual responsive hydroxyapatite capped mesoporous silica nanoparticles for controlled delivery of Palbociclib to treat osteosarcoma
Heydari, S. R., Samadi, M., Shirangi, A., Farokhi, M., Moradi, A., Bafkary, R., Atyabi, F., Mottaghitalab, F., & Dinarvand, R. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104356 · Cited by 7
NEK6 Promotes the Progression of Osteosarcoma Through Activating STAT3 Signaling Pathway by Down-Regulation of miR-26a-5p
Zhu, M., Sun, Y., Xue, H., Wu, G., Wang, Z., Shi, J., Ma, J., Gu, B., & Xiao-ling, Y. A. N. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s413461 · Cited by 7
Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma
Wedekind, M. F., & Cripe, T. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_5 · Cited by 7
Somatic and germline analysis of a familial Rothmund–Thomson syndrome in two siblings with osteosarcoma
Gutiérrez-Jimeno, M., Panizo, E., Tamayo, I., San-Julián, M., Catalán-Lambán, A., Alonso, M. M., & Patiño‐García, A. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-00160-x · Cited by 7
Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy
Kou, F., Wu, L., Guo, Y. H., Zhang, B., Li, B., Huang, Z., Ren, X., & Yang, L. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0728 · Cited by 5
MicroRNA-886 suppresses osteosarcoma cell proliferation and its maturation is suppressed by long non-coding RNA OXCT1-AS1
Dai, W., & Liu, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2031669 · Cited by 7
Self-citation
Transcriptomic Analysis of Canine Osteosarcoma from a Precision Medicine Perspective Reveals Limitations of Differential Gene Expression Studies
Nance, R. L., Cooper, S. J., Starenki, D., Wang, X., Matz, B. M., Lindley, S. S., Smith, A. N., Smith, A. A., Bergman, N. S., Sandey, M., et al. (2022) · Genes · doi:10.3390/genes13040680 · Cited by 7
A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial Results
Childs, A., Gerrand, C., Brennan, B. M. D., Young, R., Rankin, K. S., Parry, M., Stevenson, J. D., Flanagan, A. M., Taylor, R. M., Fern, L. A., et al. (2024) · Cancers · doi:10.3390/cancers16132351 · Cited by 6
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions
Frankenbach-Désor, T., Niesner, I. C. C., Ahmed, P., Dürr, H. R., Klein, A., Knösel, T., Gospos, J. P., McGovern, J., Hutmacher, D. W., Holzapfel, B. M., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10218-2 · Cited by 7
Clonal evolution and therapy resistance in the era of precision cancer medicine: evolutionary trajectories in pediatric cancer
Karlsson, J., Briggs, M., Vedi, A., & Gisselsson, D. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.001 · Cited by 6
Multifunctional nanoplatforms deciphering immune resistance in bone tumors: cooperative delivery, immune reprogramming and microenvironment remodeling
Li, J., Yang, C., Wang, L., & Li, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04243-2 · Cited by 6
Advances in Nano-Drug Delivery Systems for Osteosarcoma: From Targeting Strategies to Combating Lung Metastasis
Jia, S., Gong, B., Chen, H., Chen, Y., Zhuo, C., Wu, H., Qu, X., & Cai, H. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s586319 · Cited by 9
Sleeping Beauty Mouse Models of Cancer: Microenvironmental Influences on Cancer Genetics
Guimarães-Young, A., Feddersen, C. R., & Dupuy, A. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00611 · Cited by 7
Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease
Reed, D. R., Hingorani, P., & Anderson, P. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_8 · Cited by 6
Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo
Shimizu, T., Sugihara, E., Takeshima, H., Nobusue, H., Yamaguchi, R., Yamaguchi‐Iwai, S., Fukuchi, Y., Ushijima, T., Muto, A., & Saya, H. (2022) · Cells · doi:10.3390/cells11223614 · Cited by 6
Circ_0000253 promotes the progression of osteosarcoma via the miR-1236-3p/SP1 axis
Xu, L., Duan, J., Li, M., Zhou, C., & Wang, Q. (2022) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgac081 · Cited by 6
Establishment of Rapid and Accurate Screening System for Molecular Target Therapy of Osteosarcoma
Sasa, K., Saito, T., Kurihara, T., Hasegawa, N., Sano, K., Kubota, D., Akaike, K., Okubo, T., Hayashi, T., Takagi, T., et al. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221138217 · Cited by 6
EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis
Dai, Z., Liu, Z., Yang, R., Cao, W., & Ji, T. (2023) · Biomolecules · doi:10.3390/biom13020327 · Cited by 7
Comprehensive landscape of TGFβ-related signature in osteosarcoma for predicting prognosis, immune characteristics, and therapeutic response
Liu, D., Ye, P., Li, X., Zhu, Z., Mi, Z., Zhang, Z., & Fan, H. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100484 · Cited by 8
Mechanisms Underpinning Osteosarcoma Genome Complexity and EvolutionPreprint
Valle-Inclán, J. E., Noon, S. D., Trevers, K. E., Elrick, H., Tanguy, M., Butters, T., Muyas, F., Amary, F. M., Tirabosco, R., Giess, A. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.29.573403 · Cited by 6
Age-related genomic alterations and chemotherapy sensitivity in osteosarcoma: insights from cancer genome profiling analyses
Outani, H., Ikegami, M., Imura, Y., Nakai, S., Takami, H., Kotani, Y., Inoue, A., & Okada, S. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02673-2 · Cited by 6
Network pharmacology-based research on the effect of Scutellaria baicalensis on osteosarcoma and the underlying mechanism
Zhang, L., Tian, Y., Wang, J., Deng, S., & Fan, H. (2023) · Medicine · doi:10.1097/md.0000000000035957 · Cited by 5
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
Takagi, S., Nakajima, M., Koike, S., Takami, M., Sugiura, Y., Sakata, S., Baba, S., Takemoto, A., Huang, T., Seto, Y., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03251-6 · Cited by 5
Long non-coding RNA AC133552.2: biomarker and therapeutic target in osteosarcoma via PANoptosis gene screening
Zhao, W., Wang, Y., Zhu, J., Arya, S., Huang, G., Li, S., Chen, Q., Liu, X., Yuan, J., & Jia, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-93167-2 · Cited by 5
Mir-1247 Affects the Proliferation, Invasion and Apoptosis of Osteosarcoma Cells through SOX9
Cao, L., Yang, D., & Bai, B. (2021) · ONCOLOGIE · doi:10.32604/oncologie.2021.014151 · Cited by 5
The expression of miR‐181b, CYLD, CBX‐7, BCL2, and p53 in osteosarcoma patients and correlation with clinicopathological factors
Fazli, J., Fattah, K., Moliani, A., Valizadeh, A., & Bazavar, M. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14144 · Cited by 5
Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers
Zhang, C., Ren, X., Liu, Z., & Tu, C. (2020) · BMC Cancer · doi:10.1186/s12885-020-07348-5 · Cited by 5
Integrated Genomic Profiling and Drug Screening of Patient-Derived Cultures Identifies Individualized Copy Number-Dependent Susceptibilities Involving PI3K Pathway and 17q Genes in Neuroblastoma
Wong, R. L. Y., Wong, M. R. E., Kuick, C. H., Saffari, S. E., Wong, M. K., Tan, S. H., Merchant, K. Z., Chang, K. T. E., Thangavelu, M. T., Periyasamy, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.709525 · Cited by 4
Evaluation of the pan‐class I phosphoinositide 3‐kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma
Harrison, D. J., Gill, J. B., Roth, M. E., Hingorani, P., Zhang, W., Teicher, B. A., Earley, E. J., Erickson, S. W., Gatto, G., Kurmasheva, R. T., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.30017 · Cited by 5
Molecular features and predictive models identify the most lethal subtype and a therapeutic target for osteosarcoma
Zheng, K., Hou, Y., Zhang, Y., Wang, F., Sun, A., & Dong, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1111570 · Cited by 5
The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers
Liang, J., Chen, D., Chen, L., She, X., Zhang, H., & Xiao, Y. (2020) · Future Oncology · doi:10.2217/fon-2020-0118 · Cited by 5
Identification of potential modulators of osteosarcoma metastasis by high‐throughput cellular screening of natural products
Long, S. A., Huang, S., Kambala, A., Ren, L., Wilson, J. A., GOETZ, M. A., Hao, X., Yang, X., Goncharova, E. I., Jia, L., et al. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13762 · Cited by 5
Combining targeted sequencing and ultra-low-pass whole-genome sequencing for accurate somatic copy number alteration detection
Fu, J., Guo, W., Yan, C., Lv, Z., Wang, Y., Wang, Z., Fan, Z., & Lei, T. (2021) · Functional & Integrative Genomics · doi:10.1007/s10142-021-00767-y · Cited by 5
Addressing the knowledge gap in the genomic landscape and tailored therapeutic approaches to adolescent and young adult cancers
Hayashi, N., Ono, M., Fukada, I., Yamazaki, M., Sato, N., Hosonaga, M., Wang, X., Kaneko, K., Arakawa, H., Habano, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103659 · Cited by 4
Evaluating Circulating Biomarkers for Diagnosis, Prognosis, and Tumor Monitoring in Pediatric Sarcomas: Recent Advances and Future Directions
Maqueda, J. J., De Feo, A., & Scotlandi, K. (2024) · Biomolecules · doi:10.3390/biom14101306 · Cited by 4
ESPN activates ZEB1-mediated EMT through the PI3K/AKT/mTOR axis to promote osteosarcoma metastasis
Zhou, R., Wu, H., You, H., Wang, X., Yuan, X., Sun, Z., Zhou, D. F., Jiang, Y., & Shen, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06500-8 · Cited by 4
Advancing Preclinical Biology for Ewing Sarcoma: An International Effort
Cruz, F. S. D., Stewart, E. A., Surdez, D., Daley, J. D., Soragni, A., Tomazou, E. M., Alvarez-Perez, J., Feinberg, T. Y., Amatruda, J. F., Ganapathi, S. S., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0428 · Cited by 6
ENO1 promotes cancer metastasis via stimulating metabolism reprogramming in osteosarcoma
Huang, P., He, S., Qi, Z., Nijiati, Y., Wang, J., Lin, Z., Ma, Y., Dong, R., Chen, G., & Ning, B. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03182-3 · Cited by 5
CircAGFG1 Promotes Osteosarcoma Progression and Stemness by Competing with miR-302a-3p to Upregulate the Expression of LATS2
Li, T., Xing, G., Lu, L., Kong, X., & Guo, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6370766 · Cited by 4
Retracted
Propofol Regulates ER Stress to Inhibit Tumour Growth and Sensitize Osteosarcoma to Doxorubicin
Hua, W., Du, X., Zhao, H., Sun, P., & Yang, J. (2023) · International Journal of Clinical Practice · doi:10.1155/2023/3093945 · Cited by 4
Cuproptosis related lncRNA signature as a prognostic and therapeutic biomarker in osteosarcoma immunity
Gao, Z., Chen, S., & Ye, W. (2025) · Scientific Reports · doi:10.1038/s41598-024-84024-9 · Cited by 4
In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients
Klangjorhor, J., Phanphaisarn, A., Teeyakasem, P., Chaiyawat, P., Phinyo, P., Settakorn, J., Theera‐Umpon, N., & Pruksakorn, D. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04081-5 · Cited by 4
Advances in the role of miRNAs in the occurrence and development of osteosarcoma
Zhang, G., Li, Y., Xu, J., & Xiong, Z. (2020) · Open Medicine · doi:10.1515/med-2020-0205 · Cited by 4
Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study
Wei, R., Dean, D. C., Thanindratarn, P., Hornicek, F. J., Guo, W., & Duan, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.596330 · Cited by 4
Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma
Chi, X., Ji, T., Li, J., Xu, J. H., Tang, X., Xie, L., Meng, F., & Guo, W. (2021) · Cancer Management and Research · doi:10.2147/cmar.s317809 · Cited by 4
Risk score model of autophagy-related genes in osteosarcoma
Jiang, M., Fang, D., He, X., Huang, J., Hu, Y., Xie, M., Jike, Y., Bo, Z., & Qin, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-166 · Cited by 3
Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model
Huang, S., Ren, L., Beck, J. A., Phelps, T. E., Olkowski, C. P., Ton, A., Roy, J., White, M. E., Adler, S., Wong, K. J., et al. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2022.0090 · Cited by 4
Genome-Driven Therapy for Chemotherapy-Resistant MetastaticCDK6-Amplified Osteosarcoma
Lazow, M., Johnson, S. L., Johnson, N. D., Breneman, J. C., Dexheimer, P. J., Szabo, S., & Pressey, J. G. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00032 · Cited by 3
Development and validation of a novel endoplasmic reticulum stress-related lncRNAs signature in osteosarcoma
Xu, P., Yuan, J., Li, K., Wang, Y., Wu, Z., Zhao, J., Li, T., Wu, T., Miao, X., He, D., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76841-9 · Cited by 3
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma
Manara, M. C., Bruzzese, F., Formentini, L., Landuzzi, L., Pazzaglia, L., Laginestra, M. A., Carrabotta, M., Roca, M. S., Iannelli, F., Grumetti, L., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03440-5 · Cited by 3
Soluble immune checkpoint factors reveal high-risk osteosarcoma subtypes and enable early metastasis prediction
Peng, H., Li, B., Cui, J., Sun, G., Wang, Q., Zhu, Y., Wang, S., Tu, H., Wu, X., & Ye, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1651051 · Cited by 3
Integrative biomarker and drug target discovery in osteosarcoma: traditional experimental approaches and AI-enabled insights
Gao, Z., & Wu, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1791228 · Cited by 3
Circle RNA circCSPP1 promotes human osteosarcoma cell proliferation and increases glucose metabolism by suppressing miR-200c maturation
Zhang, L., Yang, S., Wang, C., Zhang, L., Zhang, X., Li, F., Wang, S., & Ma, K. (2022) · Human & Experimental Toxicology · doi:10.1177/09603271221097364 · Cited by 3
Targeting cancer-induced skeletal damage: a holistic approach to understanding pathophysiology, mechanisms, and management solutions
Gu, X. (2025) · American Journal of Cancer Research · doi:10.62347/qfhj2430 · Cited by 3
LINC00673 promotes osteosarcoma progression through the miR-92b-3p/DUSP1 axis
Zhang, K., Du, M., Chen, M., Zhang, Y., Shi, K., Zhang, D., Wang, X., & Zhou, Y. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156253 · Cited by 3
Distinct genomic features between osteosarcomas firstly metastasing to bone and to lung
Xie, L., Cai, Z., Lu, H., Meng, F., Zhang, X., Luo, K., Su, X., Yan, L., Xu, J., Lou, J., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15527 · Cited by 3
Global Research Trends in Limb Salvage Surgery for Osteosarcoma: Findings from a Bibliometric and Visualized Analysis over 15 Years
Raj, M., Arnav, A., Pal, A. K., & Mondal, S. (2023) · Indian Journal of Orthopaedics · doi:10.1007/s43465-023-01005-2 · Cited by 3
Network pharmacology-based research on the effect of Radix Astragali on osteosarcoma and the underlying mechanism
Zhang, Y., Wei, J., Kong, L., Song, M., Zhang, Y., Xiao, X., Cao, H., & Jin, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-49597-x · Cited by 3
Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma
Yang, Y.-T., Engleberg, A. I., & Yuzbasiyan‐Gurkan, V. (2023) · Cells · doi:10.3390/cells13010025 · Cited by 4
Analysis of cancer multigene panel testing for osteosarcoma in pediatric and adults using the center for cancer genomics and advanced therapeutics database in Japan
Suehara, Y., Kitada, R., Kamio, S., Ogura, K., Iwata, S., Kobayashi, E., Kawai, A., & Khosaka, S. (2024) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2024.10.016 · Cited by 3
Osteosarcoma in One of Identical Twins: Three Cases Report and a Literature Review
Zhao, J., Wang, W., Liu, Z., Xiao, L., Cai, Q., & Yu, X. (2021) · Orthopaedic Surgery · doi:10.1111/os.13004 · Cited by 3
Extrachromosomal DNA associates with poor survival across a broad spectrum of childhood solid tumorsPreprint
Chapman, O. S., Sridhar, S., Chow, E. Y., Kenkre, R., Kirkland, J., Dutta, A., Wang, S., Goto, R., Zhang, W., Brown, M., et al. (2025) · medRxiv · doi:10.1101/2025.07.22.24308163 · Cited by 4
Paucatalinone A from Paulownia Catalpifolia Gong Tong Elicits mitochondrial-mediated cancer cell death to combat osteosarcoma
Wang, G., Cui, Z., Tian, J., Li, X., Tang, W., Jing, W., Li, A., & Zhang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1367316 · Cited by 2
SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types
Verdier, E., Gaspar, N., Costa, M. E. M. D., & Marchais, A. (2025) · Oncotarget · doi:10.18632/oncotarget.28688 · Cited by 2
Dynorphin A Impairs Mitochondrial Biogenesis in Osteosarcoma Cells by Increasing SP‐1
Dai, Y., Zhang, J., Peng, Y., & Hu, L. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70451 · Cited by 2
Targeting developmental vulnerabilities in childhood sarcomas
Young, E., Kelly, B., & Cain, J. E. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10286-y · Cited by 2
Personalized prediction of chemotherapy efficacy in osteosarcoma through patient-derived organoids: correlation with survival and tumor proliferation potential
Nie, J., Wan, C.-Y., Li, H., Zhou, J.-L., Zhong, G.-Q., Yang, T., Yao, M.-Y., Huang, W., Zhang, C., Li, S., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03541-1 · Cited by 3
Targeting strategies and immune regulatory mechanisms of CAR-macrophages in the treatment of osteosarcoma
Rongrong, C. (2025) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2025.102602 · Cited by 2
The synergistic role of ferroptosis in osteosarcoma immunotherapy
Tian, D., Yang, Z., Zhang, J., Yang, R., & Hao, H. (2025) · Medical Oncology · doi:10.1007/s12032-025-03196-0 · Cited by 2
METTL3-mediated m6A modification of CACNA1E promotes osteosarcoma progression and chemoresistance by enhancing WNT7B-mediated Ca2+ signaling
Chen, C., Xiong, K., Liang, F., Zhong, Y., Qin, X., Huang, N., Fang, Y., Zhu, B., Cheng, J., Wei, Q., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02553-x · Cited by 2
Advances in targeted therapies for pediatric tumors
Liu, J.-Y., Yang, D.-L., Liu, H.-Y., Xiang, S.-F., Cao, J., Yang, B., He, Q.-J., Wang, J., Shao, X., & Ying, M.-D. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01805-w · Cited by 2
Self-citation

Authors: Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., Hazard, F. K., Spunt, S. L., Marina, N., Kim, G. E., Cho, S.-J., Avedian, R. S., Mohler, D. G., Kim, M.-O., DuBois, S. G., Hawkins, D. S., & Sweet-Cordero, E. A.
Affiliations: University of California, San Francisco (US)
1Division of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, California.
Stanford Medicine (US)
Harvard University (US)
Seattle Children's Hospital (US)
ORCID: Sayles, Leanne C.
Breese, Marcus R.
Koehne, Amanda L.
Leung, Stanley G.
Lee, Alex G.
Spillinger, Aviv
Shah, Avanthi T.
Hazard, Florette K.
Spunt, Sheri L.
Marina, Neyssa
Kim, Grace E.
Cho, Soo-Jin
Avedian, Raffi S.
Mohler, David G.
Kim, Mi-Ok
DuBois, Steven G.
Hawkins, Douglas S.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2019-01-01
Volume: 9
Issue: 1
Pages: 46-63
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-17-1152
PMC: PMC7134333
OpenAlex: W2892650455
Cited by: 452
References: 78
Citations by year: 2026: 48 · 2025: 59 · 2024: 67 · 2023: 84 · 2022: 63 · 2021: 63 · 2020: 52 · 2019: 14
FWCI: 24.47
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: HHS | National Institutes of Health (NIH) (S10OD018220, P30CA082103, 2T32OD011121-11, R25 CA180993-02)
Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels (Hope On Wheels)
Stanford University School of Medicine (Stanford School of Medicine, Stanford University) (Morgridge Scholar Grant)
St. Baldrick's Foundation (Team Clarkie)
CureSearch for Children's Cancer
Sarcoma Foundation of America (SFA)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: osteosarcoma, somatic copy number alterations, structural rearrangement, targeted therapy, patient-derived xenografts, copy number amplification, gene expression changes, oncogenic drivers
MeSH terms: Whole Genome Sequencing, Animals, Bone Neoplasms, Humans, Osteosarcoma, Sequence Analysis, RNA, Xenograft Model Antitumor Assays, Genomics, Mice, Genomic Structural Variation, DNA Copy Number Variations, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genome-Informed Targeted Therapy for Osteosarcoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks